Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases. The company offers antibody identification and discovery services; and a range of antibody engineering services for various stages of therapeutic and diagnostic antibody development. It also engages in the humanization of monoclonal antibodies. In addition, the company provides antibody sequencing services; custom expression and purification of recombinant proteins; transient protein expression; and stable cell line development services, as well as antibody analysis services. It serves pharmaceuticals, biotech, and diagnostic companies worldwide. The company has a collaboration partnership with Celonic AG for the development of high yield stable cell lines. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+44-28-90432800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales£2.18 million
Profitability
Miscellaneous
Employees22
Next Earnings DateN/A
OptionableNot Optionable
Fusion Antibodies (LON:FAB) Frequently Asked Questions
What is Fusion Antibodies' stock symbol?
Fusion Antibodies trades on the London Stock Exchange (LON) under the ticker symbol "FAB."
Has Fusion Antibodies been receiving favorable news coverage?
Media coverage about FAB stock has been trending negative this week, according to InfoTrie Sentiment. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Fusion Antibodies earned a media sentiment score of -2.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Fusion Antibodies.
Who are some of Fusion Antibodies' key competitors?
Some companies that are related to Fusion Antibodies include OptiBiotix Health (OPTI), Faron Pharmaceuticals Oy (FARN), Promis Neurosciences (PMN), Mereo BioPharma Group (MPH), Covalon Technologies (COV), Tiziana Life Sciences (TILS), Novoheart (NVH), AquaBounty Technologies (AQB), Verona Pharma (VRP), Zelda Therapeutics (ZLD), Noxopharm (NOX), Biotron (BIT), Actinogen Medical (ACW), ReNeuron Group (RENE) and Rezolute (RZLT).
What other stocks do shareholders of Fusion Antibodies own?
Who are Fusion Antibodies' key executives?
Fusion Antibodies' management team includes the folowing people:
- Dr. Paul Gerard Kerr, CEO & Director (Age 47)
- Mr. James Fair, CFO, Company Sec. & Director (Age 53)
- Dr. Richard John Buick, CTO & Director (Age 42)
- Prof. Jim Johnston, Founder
How do I buy shares of Fusion Antibodies?
Shares of FAB and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Fusion Antibodies' stock price today?
One share of FAB stock can currently be purchased for approximately GBX 66.50.
How big of a company is Fusion Antibodies?
What is Fusion Antibodies' official website?
How can I contact Fusion Antibodies?
Fusion Antibodies' mailing address is Springbank Industrial Estate 1 Springbank Road, BELFAST, NIR BT17 0QL, United Kingdom. The company can be reached via phone at +44-28-90432800.
MarketBeat Community Rating for Fusion Antibodies (LON FAB)
MarketBeat's community ratings are surveys of what our community members think about Fusion Antibodies and other stocks. Vote "Outperform" if you believe FAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
